Jan Vydra

1.0k total citations
45 papers, 454 citations indexed

About

Jan Vydra is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Oncology. According to data from OpenAlex, Jan Vydra has authored 45 papers receiving a total of 454 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 14 papers in Public Health, Environmental and Occupational Health and 13 papers in Oncology. Recurrent topics in Jan Vydra's work include Acute Myeloid Leukemia Research (20 papers), Hematopoietic Stem Cell Transplantation (19 papers) and Acute Lymphoblastic Leukemia research (14 papers). Jan Vydra is often cited by papers focused on Acute Myeloid Leukemia Research (20 papers), Hematopoietic Stem Cell Transplantation (19 papers) and Acute Lymphoblastic Leukemia research (14 papers). Jan Vydra collaborates with scholars based in Czechia, Italy and France. Jan Vydra's co-authors include Ryan Shanley, Jo‐Anne H. Young, Daniel J. Weisdorf, Abigail R. Smith, Isaac George, Martin Černý, T. Soukup, Tomáš Kozák, Šoňa Peková and Soňa Fraňková and has published in prestigious journals such as Blood, Cancer and Clinical Infectious Diseases.

In The Last Decade

Jan Vydra

40 papers receiving 448 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jan Vydra Czechia	10	132	123	110	89	87	45	454
Donglin Yang China	12	124 0.9×	70 0.6×	202 1.8×	102 1.1×	137 1.6×	87	527
Marcos Arango Colombia	14	120 0.9×	199 1.6×	95 0.9×	32 0.4×	236 2.7×	25	502
Renate Slind Olsen Sweden	12	89 0.7×	134 1.1×	8 0.1×	164 1.8×	28 0.3×	16	352
Hisayuki Ogura Japan	14	62 0.5×	72 0.6×	12 0.1×	102 1.1×	236 2.7×	59	519
Remzi Onur Eren Switzerland	10	62 0.5×	110 0.9×	34 0.3×	414 4.7×	185 2.1×	13	862
Peter W. Gasper United States	14	40 0.3×	29 0.2×	47 0.4×	162 1.8×	133 1.5×	28	579
Laurence Stensland United States	8	73 0.6×	94 0.8×	23 0.2×	114 1.3×	357 4.1×	10	470
Frank Griffin United States	11	23 0.2×	44 0.4×	35 0.3×	101 1.1×	126 1.4×	21	502
Alain Gumy Switzerland	7	126 1.0×	47 0.4×	33 0.3×	40 0.4×	209 2.4×	8	806
Donald C. Abele United States	15	45 0.3×	119 1.0×	34 0.3×	87 1.0×	69 0.8×	30	739

Countries citing papers authored by Jan Vydra

Since Specialization

Citations

This map shows the geographic impact of Jan Vydra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Vydra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Vydra more than expected).

Fields of papers citing papers by Jan Vydra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Vydra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Vydra. The network helps show where Jan Vydra may publish in the future.

Co-authorship network of co-authors of Jan Vydra

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Vydra. A scholar is included among the top collaborators of Jan Vydra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Vydra. Jan Vydra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brodská, Barbora, Kateřina Kuželová, Jiří Hrdý, et al.. (2025). TGF-β Decreases NK Cell Mobility and Cytotoxic Efficacy in Complex in vitro Models of the Leukemia Microenvironment. ImmunoTargets and Therapy. Volume 14. 589–604. 1 indexed citations

Sanz, Jaime, Myriam Labopin, Jurjen Versluis, et al.. (2025). Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leukemia working party of the EBMT. Bone Marrow Transplantation. 60(4). 529–534.

Blaise, Didier, Stéfania Bramanti, Mi Kwon, et al.. (2025). Impact of the addition of antithymocyte globulin to post‐transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post‐transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation. British Journal of Haematology. 207(4). 1529–1537. 1 indexed citations

Sanz, Jaime, Alexander Kulagin, Nicolaus Kröger, et al.. (2024). Ptcy Overcomes HLA Mismatch in Unrelated Donor Transplant for Acute Lymphoblastic Leukemia: A Study from the ALWP of the EBMT. Blood. 144(Supplement 1). 3570–3570.

Nagler, Arnon, Myriam Labopin, Didier Blaise, et al.. (2024). Young (<35 years) haploidentical versus old (≥35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation. 59(11). 1552–1562. 5 indexed citations

Baron, Frédéric, Myriam Labopin, Jurjen Versluis, et al.. (2024). Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American Journal of Hematology. 99(12). 2296–2305.

Shimoni, Avichai, Christophe Peczynski, Myriam Labopin, et al.. (2024). Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia. Leukemia. 39(1). 222–228. 2 indexed citations

Piemontese, Simona, Myriam Labopin, Goda Choi, et al.. (2024). Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide. Leukemia. 38(9). 2016–2022. 1 indexed citations

Roubalová, K, et al.. (2023). Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy. Leukemia Research. 130. 107314–107314. 1 indexed citations

10.

Vydra, Jan, et al.. (2023). A Phase I Trial of Allogeneic γδ T Lymphocytes From Haploidentical Donors in Patients With Refractory or Relapsed Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 23(5). e232–e239. 22 indexed citations

11.

Pytlík, Robert, Lucie Šrámková, Marek Trněný, et al.. (2023). Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome. Pathology & Oncology Research. 29. 1610914–1610914. 7 indexed citations

12.

Nagler, Arnon, Myriam Labopin, Alexander Kulagin, et al.. (2023). Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation. 58(5). 552–557. 2 indexed citations

13.

Němečková, Šárka, et al.. (2022). Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor. Current Oncology. 29(5). 2928–2934. 1 indexed citations

14.

Vydra, Jan, Veronika Válková, Michal Kolář, et al.. (2019). Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Aplasia After Cladribine/Cytarabine Chemotherapy for Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. Clinical Lymphoma Myeloma & Leukemia. 19(6). 365–371. 1 indexed citations

15.

Šroubek, Filip, Michal Bartoš, Jan Schier, et al.. (2019). A computer-assisted system for handheld whole-breast ultrasonography. International Journal of Computer Assisted Radiology and Surgery. 14(3). 509–516. 4 indexed citations

16.

Vydra, Jan, Cyril Šálek, Jiřı́ Schwarz, et al.. (2017). Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission. Clinical Lymphoma Myeloma & Leukemia. 18(2). 106–113. 2 indexed citations

17.

Üstün, Celalettin, Jiří Slabý, Ryan Shanley, et al.. (2012). Human Parainfluenza Virus Infection after Hematopoietic Stem Cell Transplantation: Risk Factors, Management, Mortality, and Changes over Time. Biology of Blood and Marrow Transplantation. 18(10). 1580–1588. 49 indexed citations

18.

Peková, Šoňa, et al.. (2011). Candidatus Neoehrlichia mikurensis infection identified in 2 hematooncologic patients: benefit of molecular techniques for rare pathogen detection. Diagnostic Microbiology and Infectious Disease. 69(3). 266–270. 61 indexed citations

19.

Šálek, Cyril, Jan Trka, Jan Vydra, et al.. (2010). [Treatment of adult acute lymphoblastic leukemia according to GMALL 07/2003 study protocol in the Czech Republic - the first experience].. PubMed. 56(3). 176–82. 7 indexed citations

20.

Šloncová, Eva, et al.. (1993). Activity of PDGF (A) gene in the human cell line derived from a renal carcinoma metastasis.. PubMed. 39(1). 40–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact